Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathw… Read more
Glaukos Corp (GKOS) - Total Liabilities
Latest total liabilities as of September 2025: $229.84 Million USD
Based on the latest financial reports, Glaukos Corp (GKOS) has total liabilities worth $229.84 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Glaukos Corp - Total Liabilities Trend (2012–2024)
This chart illustrates how Glaukos Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Glaukos Corp Competitors by Total Liabilities
The table below lists competitors of Glaukos Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tempus AI, Inc. Class A Common Stock
NASDAQ:TEM
|
USA | $1.78 Billion |
|
SiteOne Landscape Supply Inc
NYSE:SITE
|
USA | $1.54 Billion |
|
BlueScope Steel Limited
PINK:BLSFF
|
USA | $4.39 Billion |
|
Indian Oil Corporation Limited
NSE:IOC
|
India | ₹3.15 Trillion |
|
Global Unichip Corp
TW:3443
|
Taiwan | NT$15.53 Billion |
|
Mirvac Group
PINK:MRVGF
|
USA | $5.30 Billion |
|
Galp Energia SGPS S.A
OTCGREY:GLPEF
|
USA | $10.40 Billion |
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $3.12 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Glaukos Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Glaukos Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Glaukos Corp (2012–2024)
The table below shows the annual total liabilities of Glaukos Corp from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $207.82 Million | -56.58% |
| 2023-12-31 | $478.65 Million | -12.04% |
| 2022-12-31 | $544.16 Million | +0.46% |
| 2021-12-31 | $541.68 Million | +60.23% |
| 2020-12-31 | $338.05 Million | +132.93% |
| 2019-12-31 | $145.13 Million | +338.32% |
| 2018-12-31 | $33.11 Million | +19.82% |
| 2017-12-31 | $27.63 Million | +61.63% |
| 2016-12-31 | $17.10 Million | -20.37% |
| 2015-12-31 | $21.47 Million | -88.51% |
| 2014-12-31 | $186.93 Million | +3.89% |
| 2013-12-31 | $179.92 Million | +1174.39% |
| 2012-12-31 | $14.12 Million | -- |